en
Feedback
Pediatrics

Pediatrics

Open in Telegram

libros y aplicaciones para pediatria

Show more

📈 Analytical overview of Telegram channel Pediatrics

Channel Pediatrics (@librospediatria) in the English language segment is an active participant. Currently, the community unites 20 520 subscribers, ranking 1 113 in the Medicine category and 570 in the United Kingdom region.

📊 Audience metrics and dynamics

Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 20 520 subscribers.

According to the latest data from 07 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 537 over the last 30 days and by 20 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 0%. Within the first 24 hours after publication, content typically collects N/A% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 0 views. Within the first day, a publication typically gains 0 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 0.
  • Thematic interests: Content is focused on key topics such as act, exacerbation, pediatric, guideline, 0–27.

📝 Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
libros y aplicaciones para pediatria

Thanks to the high frequency of updates (latest data received on 08 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

20 520
Subscribers
+2024 hours
+1287 days
+53730 days
Attracting Subscribers
September '26
September '26
+128
in 0 channels
August '26
+556
in 0 channels
Get PRO
July '26
+569
in 0 channels
Get PRO
June '26
+513
in 0 channels
Get PRO
May '26
+497
in 0 channels
Get PRO
April '26
+436
in 0 channels
Get PRO
March '26
+290
in 0 channels
Get PRO
February '26
+354
in 0 channels
Get PRO
January '26
+479
in 1 channels
Get PRO
December '25
+360
in 0 channels
Get PRO
November '25
+397
in 1 channels
Get PRO
October '25
+443
in 0 channels
Get PRO
September '25
+475
in 1 channels
Get PRO
August '25
+523
in 2 channels
Get PRO
July '25
+489
in 1 channels
Get PRO
June '25
+363
in 0 channels
Get PRO
May '25
+468
in 1 channels
Get PRO
April '25
+485
in 0 channels
Get PRO
March '25
+550
in 2 channels
Get PRO
February '25
+463
in 3 channels
Get PRO
January '25
+802
in 1 channels
Get PRO
December '24
+908
in 0 channels
Get PRO
November '24
+917
in 0 channels
Get PRO
October '24
+1 064
in 1 channels
Get PRO
September '24
+821
in 0 channels
Get PRO
August '24
+773
in 0 channels
Get PRO
July '24
+517
in 1 channels
Get PRO
June '24
+547
in 0 channels
Get PRO
May '24
+704
in 0 channels
Get PRO
April '24
+563
in 0 channels
Get PRO
March '24
+562
in 0 channels
Get PRO
February '24
+476
in 0 channels
Get PRO
January '24
+413
in 1 channels
Get PRO
December '23
+322
in 2 channels
Get PRO
November '23
+44
in 0 channels
Get PRO
October '23
+41
in 0 channels
Get PRO
September '23
+95
in 0 channels
Get PRO
August '23
+25
in 0 channels
Get PRO
July '23
+75
in 0 channels
Get PRO
June '23
+27
in 0 channels
Get PRO
May '23
+55
in 0 channels
Get PRO
April '23
+24
in 0 channels
Get PRO
March '23
+25
in 0 channels
Get PRO
February '23
+30
in 0 channels
Get PRO
January '23
+44
in 0 channels
Get PRO
December '22
+63
in 0 channels
Get PRO
November '22
+72
in 0 channels
Get PRO
October '22
+40
in 0 channels
Get PRO
September '22
+36
in 0 channels
Get PRO
August '22
+58
in 0 channels
Get PRO
July '22
+58
in 0 channels
Get PRO
June '22
+87
in 0 channels
Get PRO
May '22
+105
in 0 channels
Get PRO
April '22
+85
in 0 channels
Get PRO
March '22
+152
in 0 channels
Get PRO
February '22
+400
in 0 channels
Get PRO
January '22
+1 362
in 0 channels
Date
Subscriber Growth
Mentions
Channels
07 September+20
06 September+18
05 September+11
04 September+18
03 September+11
02 September+37
01 September+13
Channel Posts
+1
Pediatrics In Review - June 2026.pdf1.61 MB

2
GINA 2026 Ingles+3
GINA 2026 Ingles
5 475
3
GINA 2026 Españo+3
GINA 2026 Españo
5 218
4
The Harrit lane 24th ed. 2027.pdf
6 548
5
PALS 2025.pdf
6 024
6
chatburn_2026_how_to_interpret_ventilator_waveforms_using_the_taxonomy.pdf
0
7
Pals Español_2025.pdf
0
8
Guidelines_for_the_Management_of_Severe_Traumatic.97250__2_.pdf
0
9
From now on, BiliApp is recognised as a digital health innovation application, as it is included in the Digital Solutions Cat
From now on, BiliApp is recognised as a digital health innovation application, as it is included in the Digital Solutions Catalogue of the Royal College of Paediatrics and Child Health, an academic and scientific reference institution in paediatrics in England and the United Kingdom, within its Digital Health Hub 🌐 RCPCH Digital Health Hub: https://hub.rcpch.digital/ 📲 Download BiliApp: ✅️App Store (iOS-Iphone): ✅️Google Play (Android):
0
10
Síndrome de distrés respiratorio agudo en el paciente__crítico pediátrico.pdf
0
11
2025 Textbook of Neonatal Resuscitation 9ed - AAP (1).pdf
0
12
Pediatric_Basic_Life_Support_2025_American_Heart_Association_and.pdf
0
13
Neonatal_Resuscitation_2025_American_Heart_Association_and_American.pdf
0
14
Pediatric_Advanced_Life_Support_2025_American_Heart_Association.pdf
0
15
Highlights_of_the_2025_American_Heart_Association_Guidelines_for.pdf
0
16
2025 algorithms - AHA.pdf
0
17
🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in 🇬🇧 Engl
🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in 🇬🇧 English, 🇪🇸Español, 🇧🇷 Português,🇫🇷 Français, 🇩🇪Deutsch, 🇮🇹Italiano, and 🇷🇺Русский. 📲 Download now: 🔹 App Store 🔹 Google Play
0
18
🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in English, Español, Português, Français, Deutsch, Italiano, and Русский. 📲 Download now: 🔹 App Store 🔹 Google Play
0
19
🚀 Asthma Control Test App ✅ Free tool to assess & monitor asthma control in adults and children 📱 Download here: 🍏 iPhone: Link 🤖 Android: Link 🌍 Available in 6 languages: 🇬🇧 English, 🇪🇸 Spanish, 🇫🇷 French, 🇮🇹 Italian, 🇧🇷 Portuguese, 🇩🇪 German
0
20
🌬️ Key Facts about the Asthma Control Test (ACT/C-ACT) — for Pediatricians 1️⃣ Population & instruments 👩‍🦰👦 ACT: ≥12 y (5 items, 4-week recall). C-ACT: 4–11 y (7 items; child + caregiver). [link](https://www.jacionline.org/article/S0091-6749%2807%2900167-4/fulltext) 2️⃣ Scores & cut-offs used in practice 📊 ACT: 5–25; >19 = well controlled, ≤19 = not well controlled. C-ACT: 0–27; ≤19 = not well controlled. [link](https://pubmed.ncbi.nlm.nih.gov/16522452/) | [link](https://pubmed.ncbi.nlm.nih.gov/17353040/) 3️⃣ Minimal Clinically Important Difference (MCID) 🔄 For ACT, a ±3-point change reflects a clinically meaningful improvement/worsening and predicts differential risk in outcomes. [link](https://www.jacionline.org/article/S0091-6749%2809%2901245-7/fulltext) 4️⃣ Validity & reliability (psychometrics + physiology) 📈 ACT shows internal consistency \~0.84–0.85 and test–retest \~0.77; correlates with specialist control ratings and FEV₁. [link](https://pubmed.ncbi.nlm.nih.gov/16522452/) | [link](https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/act.php) 5️⃣ Prognostic value (risk of exacerbations) 🔮 Lower ACT scores associate with higher SABA use/exacerbation risk; maintaining ACT ≥ 20 reduces exacerbation risk. [link](https://www.sciencedirect.com/science/article/pii/S0954611119300460) | [link](https://pubmed.ncbi.nlm.nih.gov/19767070/) | [link](https://pmc.ncbi.nlm.nih.gov/articles/PMC7118934/) 6️⃣ How to apply (guideline context) 🩺 Use ACT/C-ACT with symptom history, prior exacerbations, and objective measures (e.g., spirometry) to guide step-wise therapy per GINA 2024. [link](https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf)
0